14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
SPEGU vs ABUS: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Arbutus Biopharma Corporation (ABUS) is the stronger overall head-to-head candidate over Silver Pegasus Acquisition Corp Unit (SPEGU) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SPEGU carries a Unified Composite Score of 50.0/100 (HOLD) at $10.60 (N/M Forward P/E, N/A operating margin), whereas ABUS carries 43.4/100 (HOLD) at $4.02 (10.2x Forward P/E, 80.1% operating margin).
Composite vs. Pillar Nuance: While SPEGU currently prints a higher short-term Unified Composite Score (50.0/100 HOLD vs. ABUS 43.4/100 HOLD), ABUS captures the overall institutional head-to-head verdict (8–2 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (80.1% vs. N/A operating margin) and revenue trajectory (-43.5% vs. N/A YoY).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SPEGU vs ABUS. Trailing 12-month operating profitability (SPEGU N/A vs ABUS 80.1%) and valuation multiples (SPEGU N/M vs ABUS 10.2x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Blank Checks value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
ABUS Moat ProfileHigh-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $623.9M market capitalization and 80.1% operating margin.
OpEx & R&D Reinvestment11.8% of Rev ($21M)
90D Engineering Disclosures0 Published
Investor FAQ SPEGU vs ABUS Key Questions & Quantitative Answers
As of Nov 20, 2026, Arbutus Biopharma Corporation (ABUS) is the stronger overall head-to-head candidate over Silver Pegasus Acquisition Corp Unit (SPEGU) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SPEGU carries a Unified Composite Score of 50.0/100 (HOLD) at $10.60 (N/M Forward P/E, N/A operating margin), whereas ABUS carries 43.4/100 (HOLD) at $4.02 (10.2x Forward P/E, 80.1% operating margin). Composite vs. Pillar Nuance: While SPEGU currently prints a higher short-term Unified Composite Score (50.0/100 HOLD vs. ABUS 43.4/100 HOLD), ABUS captures the overall institutional head-to-head verdict (8–2 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (80.1% vs. N/A operating margin) and revenue trajectory (-43.5% vs. N/A YoY).
ABUS leads the Growth & Scale pillar: SPEGU posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with ABUS at -43.5% YoY revenue growth and +0.0% YoY earnings growth on $181M TTM revenue (91.9% gross margin, 80.1% operating margin). On trailing 12-month operating scale, SPEGU generates N/A in USD-normalized revenue versus $181M for ABUS. In operating R&D and SG&A reinvestment, SPEGU deploys N/A (0 90-day corporate R&D disclosures) versus 11.8% of Rev ($21M) (0 disclosures) for ABUS.
ABUS screens cheaper on headline valuation multiples. SPEGU trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas ABUS trades at 10.2x Forward P/E, 3.6x Trailing P/E, N/M PEG, and 2.0x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SPEGU (N/A ROE) versus ABUS (269.6% ROE) capital efficiency.
In options market volatility and institutional positioning, SPEGU carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-0.28β · 37% Vol realized risk). By comparison, ABUS carries 133.2% implied volatility (18th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.04β · 48% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.